Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA References Off-Label Use In Otherwise Bland Labeling Draft Guidance

Executive Summary

Product labels can be required to have warnings related to commonly prescribed unapproved uses with significant safety risks.

You may also be interested in...



Intercept's Ocaliva Seems Headed For Black Box On Liver Injury Risk

Physician education on dosing also likely as firm hopes to show that serious adverse events in patients with less-advanced primary biliary cholangitis may not be related to the drug.

FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

FDA's warning about 19 deaths related to excessive, off-label dosing for Ocaliva in primary biliary cholangitis spurs fears doctors will curtail prescribing and, worse, that the larger upcoming NASH market opportunity may be affected.

Rx Labeling Final Rule Largely In Line With Draft Version

New labeling format will apply initially to recently approved drugs and products receiving approval for new uses, agency says.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel